Efforts to expand access to genomic health and precision medicine have resulted in a proliferation of screening programs for healthy adult populations across the nation. Issues of fairness and equity abound in medicine and are a critical component of assessing implementation of these genomic health and precision medicine efforts. But how can programs such as genomic screening ensure equitable access within a healthcare system that is already characterized by massive health disparities and barriers to equitable access? When and how should cost-effectiveness be considered when designing screening programs and their offerings? How can cost-effectiveness models incorporate justice, equity and inclusion? In this seminar session, we will explore these questions and the overall relationship between equity and economic considerations in precision medicine.